AHL Partners’s Ligand Pharmaceuticals LGND Stock Holding History

AHL Partners’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-13,084	Closed	-$1.11M	–	1310
2017 Q3	$1.11M	Buy	13,084 +7,230	+124%	+$572K	0.02%	848
2017 Q2	$443K	Buy	+5,854	New	+$410K	0.01%	955
2016 Q1	–	Sell	-30,927	Closed	-$2.09M	–	796
2015 Q4	$2.09M	Buy	30,927 +24,236	+362%	+$1.5M	0.16%	239
2015 Q3	$358K	Sell	6,691 -69,123	-91%	-$4.19M	0.06%	502
2015 Q2	$4.77M	Buy	+75,814	New	+$4.14M	0.19%	201

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AHL Partners's LGND Position: Q4 2017 in Review

AHL Partners sold out of Ligand Pharmaceuticals (LGND) in Q4 2017, closing a stake of 13,084 shares — an estimated $1.11M sold.

AHL Partners first reported a position in LGND in Q2 2015 and held it in 5 quarters. The position peaked at $4.77M in Q2 2015. 298 funds tracked by Wall St. Rank hold LGND as of Q4 2017.

AHL Partners reported no remaining Ligand Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
AHL Partners sold 13,084 Ligand Pharmaceuticals shares in Q4 2017, an estimated $1.11M.
AHL Partners first reported a position in Ligand Pharmaceuticals in Q2 2015 and held it in 5 quarters.
AHL Partners's Ligand Pharmaceuticals position peaked at $4.77M in Q2 2015.
298 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.